News >

Olaparib Combo Shows Promise in Small Cell Lung Cancer

Jason M. Broderick @jasoncology
Published: Thursday, Aug 15, 2019

Anna Farago, MD, PhD, assistant professor of medicine at Harvard Medical School and Massachusetts General Hospital Cancer Center

Anna Farago, MD, PhDD

Combining the PARP inhibitor olaparib (Lynparza) with temozolomide (Temodar) led to an overall response rate (ORR) of 41.7% in patients with relapsed small cell lung cancer (SCLC), according to findings from a phase I/II trial published in Cancer Discovery.1,2



  1. Combinatorial Therapy Shows Early Promise in Patients With Relapsed Small Cell Lung Cancer. American Association for Cancer Research. Published August 15, 2019. Accessed August 15, 2019.
  2. Farago AF, Yeap BY, Stanzione M, et al. Combination olaparib and temozolomide in relapsed small cell lung cancer [published online August 15, 2019]. Cancer Discov. doi: 10.1158/2159-8290.CD-19-0582.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication